Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and neutralizes vascular endothelial growth factor (VEGF), a key protein involved in angiogenesis. By inhibiting VEGF, bevacizumab prevents the proliferation of endothelial cells and the formation of new blood vessels, which is critical in limiting tumor growth and metastasis. The antibody is composed of human framework regions combined with murine complementarity-determining regions and is produced using Chinese Hamster Ovary (CHO) cells.
Clinically, bevacizumab is used as an antineoplastic agent across a range of solid tumors, including colorectal, lung, breast, kidney, and glioblastoma cancers. Its anti-angiogenic properties help to reduce or halt metastatic disease progression by depriving tumors of the blood supply necessary for growth. The drug has become a key component of various chemotherapy regimens and is often evaluated for therapeutic efficacy through therapeutic drug monitoring (TDM).
In research and clinical practice, TDM of bevacizumab is employed to maintain optimal drug levels in the bloodstream, ensuring efficacy while avoiding toxicity. As with other biologics, bevacizumab’s complex structure and manufacturing process can lead to variability in immune responses, including the formation of anti-drug antibodies (ADAs). These immune reactions may affect drug pharmacokinetics and clinical effectiveness, making biomarker monitoring and individualized dosing strategies essential to patient care.
This product is manufactured in Turkey by Matriks Biotek.